GET DAILY SIGNALSCardinal Health (CAH) Delivers Strong Q1 Fiscal 2027 Results with +5% Revenue Growth
Key Takeaways
- Cardinal Health reported first-quarter fiscal 2027 revenue of $67.5 billion, up 5% year over year and ahead of consensus estimates.
- Non-GAAP diluted EPS reached $3.26, up 28% year over year and above analyst expectations; GAAP diluted EPS rose 27% to $2.38.
- Management raised its full-year fiscal 2027 adjusted EPS guidance to a range of $12.80–$13.00, up from $12.40–$12.60.
- The Pharmaceutical and Specialty Solutions segment drove the beat, while the Global Medical Products and Distribution segment posted a profit decline.
- The company completed a $500 million accelerated share repurchase and generated roughly $1.6 billion in adjusted free cash flow during the quarter.
- Additional details on CAH Major News, Today's Price Move, Price Targets, and Forecasts are available on dedicated pages.
Why This Quarter Matters
Cardinal Health’s fiscal first quarter, which ended September 30, 2026, provides a useful snapshot of pharmaceutical distribution trends and medical supplies demand. As a low-margin distributor, profitability hinges on operating leverage and strength in higher-margin specialty and growth areas. The quarter drew attention for signs of progress in the Global Medical Products and Distribution unit amid ongoing margin pressure, alongside momentum in specialty pharmaceuticals. Solid demand across the business, paired with disciplined cost control, gave management sufficient confidence to raise full-year guidance—a development worth noting for anyone following the healthcare supply chain.
The Numbers Behind the Beat
Cardinal Health reported first-quarter fiscal 2027 revenue of $67.5 billion, up 5% year over year and above consensus. Non-GAAP diluted EPS came in at $3.26, a 28% year-over-year increase that topped the analyst consensus of roughly $2.92–$2.94. On a GAAP basis, diluted EPS rose 27% to $2.38.
Adjusted operating income increased 17% to $1.0 billion, the first time the company has reached that level in a single quarter. Pharmaceutical and Specialty Solutions revenue rose 6% to $62.6 billion, with segment profit up 17% to $783 million. Global Medical Products and Distribution revenue held roughly flat at $3.2 billion, though segment profit fell 28% to $33 million. The Other segment grew revenue 7% to $1.8 billion and profit 16% to $193 million.
Management raised fiscal 2027 adjusted EPS guidance to $12.80–$13.00, from the prior range of $12.40–$12.60, pointing to robust demand and strong operational execution. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
How the Market Responded
Shares of CAH climbed on the day of the report, rising roughly 5.75% to about $276.99 after the company beat expectations and lifted its outlook. The positive reaction reflected investor approval of the earnings beat and the guidance raise, especially the strength in high-margin specialty and growth businesses. Sentiment received further support from balance-sheet actions, including the completed $500 million accelerated share repurchase. While the Global Medical Products and Distribution segment remained a soft spot, management’s comments on external cost pressures, such as petroleum-related transportation costs, did not meaningfully dampen enthusiasm around the quarter.
What to Watch Going Forward
Looking ahead, investors will monitor whether Cardinal Health can sustain the operating leverage seen in the first quarter. The raised fiscal 2027 adjusted EPS guidance of $12.80–$13.00 implies continued profit momentum, though execution across segments will be key.
In the Pharmaceutical and Specialty Solutions segment, attention will center on specialty sales growth, the generics program, and the ongoing impact of GLP-1 medication volume. Management noted that the contribution from the Solaris acquisition will be lapped beginning in the second quarter, which could affect year-over-year comparisons.
For Global Medical Products and Distribution, the focus stays on margin recovery. Management indicated that sustained high petroleum costs could push segment profit toward the low end of its $200 million–$220 million guidance range. Meanwhile, the growth businesses within the Other segment continue to benefit from trends such as an aging population and the shift toward home-based care.
Beyond operations, investors may track the anticipated completion of the AdaptHealth Diabetes Health acquisition in the third quarter of fiscal 2027 and the renewed pharmaceutical distribution agreements with CVS Health, both of which could influence revenue growth and competitive positioning.
Using AI Tools for Deeper Analysis
In my own research process, I regularly turn to Tickeron’s AI Screener when evaluating earnings movers like CAH. It helps me quickly filter for technical patterns, fundamentals, and performance metrics across thousands of stocks, making it easier to spot relevant setups without manual effort. The tool has proven useful for narrowing focus on sector themes and breakout candidates in a more efficient way.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
CAH's RSI Oscillator is staying in overbought zone for 2 days
Watch for a price pull-back in the near future.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CAH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 43%.
CAH broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 04, 2026. You may want to consider a long position or call options on CAH as a result. In 68 of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 78%.
The Moving Average Convergence Divergence (MACD) for CAH just turned positive on November 04, 2026. Looking at past instances where CAH's MACD turned positive, the stock continued to rise in 33 of 42 cases over the following month. The odds of a continued upward trend are 79%.
CAH moved above its 50-day moving average on October 08, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for CAH crossed bullishly above the 50-day moving average on October 13, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 8 of 12 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 67%.
Following a +3.74% 3-day Advance, the price is estimated to grow further. Considering data from situations where CAH advanced for three days, in 262 of 392 cases, the price rose further within the following month. The odds of a continued upward trend are 67%.
The Aroon Indicator entered an Uptrend today. In 188 of 310 cases where CAH Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 61%.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 2 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 74, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 6 (best 1 - 100 worst), indicating outstanding price growth. CAH’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 20 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 30 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-21.511) is normal, around the industry mean (14.461). CAH has a moderately high P/E Ratio (36.839) as compared to the industry average of (11.207). Projected Growth (PEG Ratio) (1.105) is also within normal values, averaging (2.016). Dividend Yield (0.008) settles around the average of (0.134) among similar stocks. P/S Ratio (0.217) is also within normal values, averaging (4.260).
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
What is the Descending Triangle (Bullish) Pattern?
Earnings Reports and Projections for the Week July 15 - 19
Swing Trading Secrets: Thriving with High Win Rates in Low Volatility
3 Points for Successful Cryptocurrency Trading Using AI Bots
How to Trade During War & Market Chaos: Tickeron's Trending Stocks AI Robot — 79%+ Win Rate Signals Across Semiconductors, Defense & Space
General Information
a maker of pharmaceuticals, medical, surgical and laboratory supplies as well as develops drug delivery systems
Industry MedicalDistributors
Advertisement